Drug Trial Radar · NCT01868061
A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication
Last checked: Nov 19, 2026Latest source record: May 19, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,068
Actual
Start
Jul 31, 2013
Primary completion
Jan 2, 2017
Study completion Jan 2, 2017
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 4, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication. Participants will be randomized in 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered as subcutaneous (SC) injection every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. Participants who were assigned to placebo during the placebo-controlled period of the trial will be re-randomized at Week 52 to receive blinded SC lebrikizumab 37.5 milligrams (mg) or 125 mg every 4 weeks from Weeks 53 to 104. The anticipated time on study treatment is 104 weeks. After study treatment, all participants will complete a 20-week safety follow-up.
Conditions
- Asthma
Interventions
LebrikizumabDrug
Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
PlaceboDrug
Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Asthma Exacerbations During the 52-Week Placebo-Controlled PeriodTime frame: Baseline up to Week 52
Locations
232 sites in 26 countries. Site status is shown where the registry gives one.
Clinical Research Center of Alabama, LLC
Birmingham, Alabama
Medical Research of Arizona; Allergy, Asthma & Immu
Scottsdale, Arizona
Quality of Life Medical & Research Center
Tucson, Arizona
Kern Allergy Med Clinic, Inc.
Bakersfield, California
Allergy and Asthma Relief Experts
Granada Hills, California
Southern California Institute For Respiratory
Los Angeles, California
Allergy & Asthma Consultants
Redwood City, California
Integrated Research Group Inc
Upland, California
Allergy & Asthma Medical Group; Clinical Research Division
Walnut Creek, California
Asthma & Allergy; Associates, P.C.
Colorado Springs, Colorado
Storms Clinical Research; Institute
Colorado Springs, Colorado
National Jewish Health
Denver, Colorado
Colorado Allergy & Asthma Centers, Pc
Denver, Colorado
Western States Clinical Research, Inc
Wheat Ridge, Colorado
Yale University School Of Medicine
New Haven, Connecticut
Allergy Consultants PA
Boca Raton, Florida
Research Institute of South Florida Inc
Miami, Florida
Sarasota Clinical Research
Sarasota, Florida
Georgia Pollens
Albany, Georgia
Brookstone Clinical Res Ctr
Columbus, Georgia
Southeast Regional Research Group
Columbus, Georgia
DataQuest Medical Research
Lawrenceville, Georgia
Aeroallergy Research Labs
Savannah, Georgia
Atlanta Allergy & Asthma Clini
Woodstock, Georgia
East-West Medical Research Institute
Honolulu, Hawaii
Asthma & Allergy of Idaho
Twin Falls, Idaho
The Allergy and Asthma Center
Fort Wayne, Indiana
Cotton O'Neil Clinic; Stormont-Vail Hlth Care
Topeka, Kansas
Dr. Paul Shapero
Bangor, Maine
Asthma, Allergy & Sinus Center
Baltimore, Maryland
Chesapeake Clinical Research
Baltimore, Maryland
Howard County Center for Lung and Sleep, LLC
Columbia, Maryland
Infinity Medical Research Inc
North Dartmouth, Massachusetts
Clinical Research Inst
Minneapolis, Minnesota
Asthma and Allergy Physicians LLC
Brockton, Mississippi
Allergy Associates, Inc.
Chesterfield, Missouri
Center For Pharmaceutical Research
Kansas City, Missouri
Clinical Research Center, L.L.C.
St Louis, Missouri
Clinical Research Consortium
Las Vegas, Nevada
Adult Pediatric Allergy Central Jersey
Edison, New Jersey
Showing 40 of 232 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.